5:33 PM
 | 
Dec 21, 2012
 |  BC Extra  |  Top Story

Halozyme, Pfizer in rHuPH20 biologics deal

Halozyme Therapeutics Inc. (NASDAQ:HALO) jumped $1.49 (27%) to $7.01 on Friday after granting Pfizer Inc. (NYSE:PFE) worldwide rights to develop and commercialize products comprising...

Read the full 106 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >